<DOC>
	<DOC>NCT00572364</DOC>
	<brief_summary>The purpose of the study is to assess the safety and tolerability of AZD2281 following single and multiple oral doses in patients in Japan with advanced solid malignancies</brief_summary>
	<brief_title>Open Label, Dose Escalation Phase I Study of AZD2281</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Poly(ADP-ribose) Polymerase Inhibitors</mesh_term>
	<criteria>Histologically or cytologically confirmed malignant solid tumour and refractory to standard therapy or for which no suitable effective standard therapy exists. Patients undergone, within 4 weeks prior to trial entry, an anticancer therapy which includes chemotherapy (or a longer period depending on the defined characteristics of the drugs used eg,. 6 weeks for mitomycin C or nitrosourea.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Advanced solid malignancies</keyword>
</DOC>